Loading
KLLN (Killin) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer and Renal cell carcinoma.
DNA-binding protein involved in S phase checkpoint control-coupled apoptosis by mediating p53/TP53-induced apoptosis. Has the ability to inhibit DNA synthesis and S phase arrest coupled to apoptosis. Has affinity to both double- and single-stranded DNA.
CIViC holds 2 clinical evidence items and 0 assertions across 1 variant.
In plain words · KLLN (Killin) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer and Renal cell carcinoma.
KLLN (Killin) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer and Renal cell carcinoma.
DNA-binding protein involved in S phase checkpoint control-coupled apoptosis by mediating p53/TP53-induced apoptosis. Has the ability to inhibit DNA synthesis and S phase arrest coupled to apoptosis.
No product in this corpus aims at KLLN yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the role biomarker; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA KLLN: RNA tissue enhanced (skeletal muscle 4 nTPM); no normal tissue stained high. Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Breast cancer (all types), Renal cell carcinoma); Open Targets associates it with 0 specific cancer types at or above 0.5. (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas KLLN tissue; Open Targets ENSG00000227268 associations
First described 2004. Earliest sequence paper UniProt cites for the protein: Deloukas et al, Nature, 2004, "The DNA sequence and comparative analysis of human chromosome 10". Source.
Sources: HGNC HGNC:37212 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt B2CW77 (protein name, function text, keywords and locations (REST API)); CIViC gene KLLN (2 evidence items, 0 assertions, 1 variants; diseases: Breast Cancer, Renal Cell Carcinoma (GraphQL API, CC0))
DNA-binding protein involved in S phase checkpoint control-coupled apoptosis by mediating p53/TP53-induced apoptosis. Has the ability to inhibit DNA synthesis and S phase arrest coupled to apoptosis. Has affinity to both double- and single-stranded DNA. Location: Nucleus (UniProt). Locus 10q23 (HGNC).
RNA: tissue enhanced (skeletal muscle 4 nTPM), detected in some normal tissues.
No normal tissue stained high.
No cancer sample stained medium or high.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"KLLN" OR ABSTRACT:"KLLN" OR TITLE:"killin, p53 regulated DNA replication inhibitor" OR ABSTRACT:"killin, p53 regulated DNA replication inhibitor" OR TITLE:"Killin" OR ABSTRACT:"Killin" OR TITLE:"killin" OR ABSTRACT:"killin") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about KLLN, not a curated reading list.